| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2026 , Vol 64 , Num 4
The role of thymic stromal lymphopoietin (TSLP): A predictive biomarker for severity and poor control in asthmatic Iraqi patients
1 Al-Nahrain University, College of Medicine, Department of Chemistry and Biochemistry, Baghdad, Iraq2 Al-Nahrain University, College of Medicine, Department of Medicine, Baghdad, Iraq
DOI : 10.23893/1307-2080.APS64028 Viewed : 101 - Downloaded : 45 Thymic stromal lymphopoietin is an epithelial-derived alarmin that triggers and enhances type 2 airway inflammation. In this case–control study, adults with asthma (n=90) and healthy controls (n=90) were enrolled. Patients were subclassified by Global Initiative for Asthma (GINA)-based severity (moderate n=56; severe n=34) and control (controlled n=31; partly controlled n=34; uncontrolled n=25). Serum Thymic stromal lymphopoietin (TSLP) was measured using ELISA technology. Non-parametric comparisons between moderate and severe asthmatic patients were conducted using the Mann–Whitney U-test and comparisons across asthma control categories were conducted using the Kruskal–Wallis with Dunn’s post-hoc tests. Receiver operating characteristic (ROC) analysis was used to estimate diagnostic accuracy. Serum TSLP was significantly higher in severe compared with moderate asthma (median 43.0 vs 26.4 pg/mL; p<0.0001). Across control categories, TSLP differed significantly (p<0.0001), with higher values in partly controlled and uncontrolled asthma compared with controlled asthma (post-hoc: Partly controlled asthma > controlled patients and uncontrolled asthma patients > controlled patients; uncontrolled asthma patients ≈ Partly controlled asthma). ROC analysis showed excellent discrimination between patients and healthy controls (AUC=0.907; 95% CI 0.855–0.945). A cut-off >19.21 pg/mL yielded 78.89% sensitivity and 92.22% specificity. High levels of serum TSLP in asthma patients who get worse and lose control suggest that it could be a good biomarker for severe and poorly managed asthma in Iraqi adults. Adding serum TSLP to multi-marker panels may improve phenotyping and risk classification. Keywords : asthma, thymic stromal lymphopoietin (TSLP), serum biomarker, asthma control, GINA